Protocol Ledger

NCT07671885 · Phase III · RECRUITING

Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)

Interventional Phase III clinical trial protocol NCT07671885 sponsored by Tokyo Women's Medical University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-28 Enrollment: 950 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07671885
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)950 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07671885
Protocol FieldVerified Registry Value
NCT IdentifierNCT07671885
Consolidated Lead SponsorTokyo Women's Medical University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment950 participants (ESTIMATED)
Registered Start Date2026-01-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI